Brook Jackson 💜 Profile picture
May 1 10 tweets 8 min read Read on X
🚨NEW: One of the most powerful legal briefs I have ever read.

To my team of attorneys — thank you for your tireless efforts, your patience, your commitment to excellence and the rule of law. The principles of humanity have been evident in every action you've taken, ensuring that justice is served with integrity. I totally admire that!

RELATOR’S SUR-REPLY TO GOVERNMENT’S LATE REPLY RE MOTION TO INTERVENE AND DISMISS

TO THE HONORABLE JUDGE OF THE COURT:

Relator Brook Jackson (“Relator”) hereby requests that the Court consider this sur-reply to the late reply of the United States of America (“Government” or “DOJ”) to Relator’s opposition to the DOJ’s motion to intervene to dismiss.

INTRODUCTION

In its effort to gain permission to intervene and dismiss this extraordinarily important False Claims Act case, the DOJ asserts several misleading half-truths. Yes, Brook Jackson’s qui tam action is brought in the name of the Government and the United States is the real party in interest. But, in making the False Claims Act “the Government’s primary litigative tool for combating fraud” “in modern times,” Congress partially assigned rights directly to relators like Brook Jackson, equipping them with authority to litigate qui tam claims without control or even direct participation of the DOJ.

Brook Jackson does not need approval of the DOJ or agency executives to fulfill her role before this Court.
Yes, Congress provided in 31 U.S.C. § 3730(c)(3) a mechanism for the Government to file a motion seeking dismissal of the qui tam action notwithstanding a relator’s objections. But, as the Supreme Court made clear, the Government first must show good cause to intervene to become a party to the action, and even then, the Government must “offer[] a reasonable argument for why the burdens of continued litigation outweigh its benefits.”

Congress intended that False Claims Act claims be dismissed for legitimate government purposes, and not as a result of fraud, illegality, or lack of political will.

And yes, the courts have, both before and after Polansky, found “good cause” for intervention under § 3730(c)(3) based on the Government’s reason for moving to dismiss under § 3730(c)(2)(A), “itself.” But in each and every case, the Government was able to show a reasoned basis for intervention and dismissal, grounded in a valid governmental purpose as exemplified in the Granston Memo.

Never before has the DOJ sought to dismiss a meritorious case like Brook Jackson’s case here, where the relator can demonstrate a strong basis to recover substantial damages for harms caused to the United States by fraud and false claims on the public fisc.

And, never before has the Government failed to even articulate a legitimate reason for dismissal.
In its late reply, the DOJ waives key points and authorities raised in the opposition. The catastrophic harms caused by Pfizer’s ineffective and unsafe modified RNA biologic, the loss of credibility in agencies and the DOJ as they abdicate public policy to partner up with corporate interests, and the essential role courts hold keeping our Government functioning in the face of executive failures, are all now undisputed.

The DOJ continues to assert an unfettered right to dismiss any qui tam action whenever it wants, without mention of the Granston Memo. It offers no explanation for how this lawsuit seeking to hold Pfizer accountable for proven fraud in the design, conduct, analysis and reporting of the clinical trials is contrary to national health policy.

The Government does not deny that dismissal would undermine the Act by sending a chilling signal to future relators that exposing fraud on the United States is futile when agency executives want that fraud kept secret. Nor does it deny that this is its true motive for seeking dismissal. The DOJ does not address Rule 24 of the Federal Rules of Civil Procedure, or the requirement under subdivision (d)(3) of that Rule that the Court consider prejudice to Brook Jackson as the original party in determining whether to grant permissive intervention. And, it completely ignores constitutional arguments regarding content-based infringement of Brook Jackson’s First Amendment right to petition, the disordering of the separation of powers to protect corporate and executive actors, and the lack of a rational basis under due process and equal protection.

While the Government possesses the authority, indeed obligation, to make a “later date” intervention to dismiss qui tam actions on good grounds based on legitimate government purposes consistent with the False Claims Act, no such showing is made here.

The DOJ’s motion should be denied without prejudice on this record. In the event that the Government seeks to intervene post-seal period based on actual evidence and articulated grounds, the Court should allow limited discovery and hold an evidentiary hearing under § 3730(c)(2)(A) and (c)(3).
SUR-REPLY ARGUMENTS

I. The DOJ Failed to Show Good Cause for Intervention
Contrary to the DOJ’s contention, no court has ever relieved the DOJ of the obligation to make a showing of good cause for a “later date” intervention under § 3730(c)(3). Every court which has found good cause to intervene based on the Government’s motion to dismiss did so because the Government had a reasonable basis for seeking dismissal: i.e., the Government “offer[ed] a reasonable argument for why the burdens of continued litigation outweigh its benefits.” Polansky., 143 S. Ct. at 1734. And, since the Supreme Court in Polansky rejected the DOJ’s assertion of unfettered discretion to dismiss, no Court has held that the government’s mere assertion of the motion, itself, satisfied good cause. In each, it was the substantive reason for the dismissal, itself, that provided good cause. The assertion of an unfettered discretion here fails to provide good cause.
Polansky provides a perfect example. In discussing the good cause finding by the Third Circuit, the Supreme Court stated the actual grounds for seeking dismissal, not the mere assertion of the unfettered right, as showing good cause. And applying that standard, the Third Circuit found that the Government’s request to dismiss the suit—based on its weighing of discovery burdens against likelihood of success—itself established good cause to intervene.

As pointed out in the opposition but ignored in the reply, these reasons for dismissal included evidence that actual “discovery burdens mounted and weighty privilege issues emerged,” and the Government had “thoroughly investigated the cost and benefits of allowing [Polansky’s] case to proceed and ha[d] come to a valid conclusion based on the results of its investigation.” 143 S. Ct. at 1729 (emphasis supplied). “Polansky [did] not challenge that conclusion.”

No such showing is made by the DOJ here.
Similarly, the DOJ ignores the actual basis for dismissal established in Brutus Trading, LLC v. Standard Chtd. Bank, 2023 U.S. App. LEXIS 21868, at *5 (2d Cir. Aug. 21, 2023).

There, the Government showed that the relator's “factual allegations were unsupported, its legal theory was not cognizable, and the continuation of the suit would waste considerable government resources.” Contrary to the DOJ’s position here, it was not the mere assertion of an unfettered right to dismiss that established good cause.

In United States ex rel. Carver v. Physicians Pain Specialists of Ala., P.C., 2023 U.S. App. LEXIS 19592, at *11-13 (11th Cir. July 31, 2023), it was the “same grounds” supporting dismissal that also established good cause, not the mere assertion of a right. (Emphasis supplied.) Those grounds included evidence that Carver had “failed to prosecute this action to an enforceable judgment, neglected her responsibilities as a relator, burdened the United States with discovery requests that are either irrelevant or premature, and undercut the United States’ FCA enforcement efforts in this district.” Id. The DOJ in Carver provided great detail for these considerations, showing that “it did not make the decision ‘lightly,’ [and] it had ‘determined that the costs of continued litigation outweigh any benefits the United States could realistically obtain.’”

No such claims could be made in connection with Brook Jackson’s lawsuit here.

In United States. ex rel. USN4U, LLC v. Wolf Creek Fed. Servs., 2023 U.S. Dist. LEXIS 217620, at *4-5 (N.D. Ohio Dec. 7, 2023), the district court expressly found that the Government had “shown good cause to intervene.” In Wolf Creek, the district court held:
Here, for good cause the U.S. contends that discovery has cast doubt on the Relator's ability to prove any False Claims Act violations against Defendants. Many of the Relator's allegations and his expert's opinions have been challenged by the testimony of the NASA employees who were deposed in this case. For example, Relator argues that NASA employees did not adequately review Defendants' proposals, but the NASA employees described a lengthy review process for the approval of the proposals. And the U.S. correctly questions the ability of Relator's expert to refute this because he was not involved in NASA's review process. See ECF Doc. 69-1 at 7. The U.S. also shares the concerns of [*5] the Court regarding Relator's credibility; his testimony during the October 4, 2023 hearing was "vague, evasive and contradictory." Id. The U.S. does not want to devote any more resources to the case given the unlikelihood of Relator's success. [Id.]

The district courts decision is currently being appealed, mainly on other grounds.

But even this ruling supports Brook Jackson here, as the DOJ fails to point to any of the factors that were found to be present there.
The DOJ disingenuously accuses Relator of asserting that courts “look beyond the flexible ‘good cause’ standard.” In fact, Relator acknowledges and embraces the good cause standard. Despite its flexible, familia and non-burdensome nature, the Government simply does not meet it. Similarly, the DOJ claims that it is not required to ground its “later date” intervention on “new evidence” or “changed circumstances,” but it cites no authority in that regard.

In contrast, Relator in her opposition quotes the Supreme Court’s decision in Polansky explaining Congress’s purpose for “good cause” later date permissive intervention, because it “knew circumstances could change and new information could come to light.” Polansky, 143 S. Ct. at 1733.

In sum, none of the courts since Polansky have agreed that the DOJ has unfettered authority to intervene to dismiss qui tam actions.

Neither the language nor the purpose of the qui tam provisions support the government assertion of that position here.
II. The DOJ Failed to Address Brook Jackson’s Constitutional Arguments

The DOJ makes little effort to address the detailed constitutional arguments presented in the opposition. In order to evade its obligation to act consistent with constitutional constraints, the DOJ suggests that Brook Jackson may petition the government elsewhere – through some “other appropriate avenues” – to raise “concerns about federal agency decision-making.”

The Government does not deny that Congress partially assigned to Relator the right to petition the Government for redress of the Goverenment’s injury. Nor does the Government refute that it would be a violation of the First Amendment to infringe on Brook Jackson’s speech in the public square based upon her viewpoint that Pfizer committed clinical trial fraud to the injury of the United States and its People. And thus, the DOJ offers no explanation for how this content-based restriction of her right to petition under the qui tam statute complies with the First Amendment.
Worse, the DOJ completely ignores the point raised in the opposition that separation of powers concerns must weigh heavily in the “good cause” determination.

Here, the DOJ’s motion to dismiss should be carefully and independently reviewed by this Article III Court, as the Government attempts to rewrite both the objective standards in EUA statute and the 1986 False Claims Act amendments which eliminated the “government knowledge” bar.

Government knowledge, acquiescence or complicity in Pfizer’s clinical trial fraud would not excuse the sponsor of its obligations to conduct non-fraudulent trials on its biologic product.

In these circumstances, the Court is the last bastion of hope for a Government that adheres to the Rule of Law.

Finally, the DOJ does not dispute, and therefore concedes, that substantive due process and equal protection require that its motion have a rational basis.

The Government’s abject failure to make a coherent explanation for dismissal means it fails even this minimal test.

There can be no doubt that protection of whistleblowers is a principal policy of the United States. So too is prevention of fraud in the design, conduct, analysis and reporting of clinical trials.

Given this, the DOJ is unable to explain to the Court, or the People, why Brook Jackson’s prosecution of this action is inconsistent with national policy.

Rather, dismissal of this case, would be.
CONCLUSION

The Court should grant leave to file this sur-reply, and deny the DOJ’s motion to intervene and dismiss for the reasons stated herein, in the opposition and at oral argument.

Respectfully 💜
@threadreaderapp unroll

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Brook Jackson 💜

Brook Jackson 💜 Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @IamBrookJackson

Feb 19
Redux & Fen-phen: These weight-loss medications were withdrawn from the market in 1997 due to reports of heart valve damage & pulmonary hypertension. The withdrawal was linked to scientific fraud and misconduct in clinical trials, where the risks were downplayed and not adequately reported.
Raxar (grepafloxacin): This antibiotic was withdrawn from the market in 1999 due to reports of serious cardiac events, including QT prolongation & torsades de pointes. Scientific misconduct was suspected in the clinical trials & safety data was misrepresented.
Darvon & Darvocet: These pain medications were withdrawn from the market in 2010 due to the risk of serious & potentially fatal heart rhythm abnormalities. Scientific fraud was not directly implicated, but concerns were raised about the efficacy & safety data that were used to support the continued use of these medications.
Read 11 tweets
Dec 20, 2023
🚨The World vs Pfizer (case update)

“The right to search for truth implies also a duty; one must not conceal any part of what one has recognized to be true.” - Albert Einstein

As indicated by the quote above, inherent in the scientific search for truth is a duty to disclose, and not conceal, any part of what is shown to be true.

Relator Jackson alleged Pfizer abandoned the scientific method and the search for truth to induce FDA’s authorization of its modRNA biologic to enable it to sell the United States 100M doses (for $1.9B). Ms. Jackson has alleged Pfizer engaged in fraud in the design, conduct, analysis and reporting of its clinical trials, and in statements it made to FDA.
In her Second Amended Complaint (SAC), Ms. Jackson details her knowledge of the particular circumstances in which Pfizer engaged in clinical trial fraud to induce FDA’s issuance of the EUA.

Among other things, this includes a trial design to avoid disclosure on immunity and transmission; short-cutting the study to conceal negative efficacy and serious adverse events; manipulation of inclusion and exclusion determinations to reach predetermined results; unblinding of subject status and then falsely reporting the occurrence or non-occurrence of adverse events based on the subject’s disclosed status; and suppression of available alternatives (Ivermectin).
The FDA’s EUAs are issued under Section 564 of the Federal Food, Drug, and Cosmetic Act. In 21 U.S. Code § 360bbb-3, Congress established objective material standards to be met by providers of medical products in emergencies and for the HHS Secretary to issue an EUA. In pertinent part, with emphasis supplied, the statute reads:Image
Read 14 tweets
Aug 1, 2023
Pfizer Court Case Update: Because we still have a pending motion before the district court that Judge Truncale has not ruled on since May, we filed a combined request for stay until he does & alternatively for an extension of time to file our initial brief due to the appellate… https://t.co/dZeYsDmocJtwitter.com/i/web/status/1…
Image
Image
Image
Read 6 tweets
May 27, 2023
How Pfizer Violated the False Claims Act:

Count 1 - Fraudulent Presentment
Pfizer presented false claims to the government for payment of a product Pfizer never delivered nor ever intended to deliver.

· Pfizer's invoices sought payment for delivering a safe, effective, vaccine… twitter.com/i/web/status/1…
Count 2 - Fraud by Express False Certification
Pfizer made express certifications to the government that the product would be delivered according to the contractual terms when it wasn't.

· Pfizer won billions of taxpayer money, and then their product caused the deaths and… twitter.com/i/web/status/1…
Count 3 - Fraud by Implied False Certification
Pfizer certified their product complied with all the regulatory requirements explicitly included in the contract, when they used the contractually required language that required a contractually compliant product in the certification… twitter.com/i/web/status/1…
Read 4 tweets
May 2, 2023
1/This is Josh Hodges, he used to work for HHS Admin for Community Living back in the day, but is now Chief Customer Officer of National Council on Aging. Today, he announced $50M in federal funding from his old buddies at HHS. The largest grant in their history! To do what? Image
2/Well, provide funding to “hundreds of diverse community-based organizations, enabling them to conduct tailored outreach, host vaccine clinics & offer services many older adults need to get vaccinated.”
3/Those services include transportation & assistance in scheduling vaccination appointments. Falls in line with the company’s mission to “reach millions of individuals and empower them to enroll in benefits programs, prevent falls, and manage their health.” Ha!
Read 7 tweets
Apr 4, 2023
1/After the initial 60 day seal expired in Mar. 2021, the DOJ requested an addt’l 6 months to “investigate” Pfizer. I reluctantly agreed b/c I was told I needed the DOJ. The weight & guilt of knowing what Pfizer did but warned not say anything was & still is unbearable at times.
2/I remember telling Joel, my former atty over & over, no more extensions! 6 months gave DOJ until Sep. 2021 or that if FDA approved the vaccine for children, I was done! I planned to go public no matter what. On Aug. 25, 2021, I sent him this email. Sorry for the language 🤷🏻‍♀️
3/In Sep. 2021, the DOJ requested another 6 month seal extension AND on Sep. 28, 2021, the FDA approved the COVID-19 vaccine for children. The call was scheduled and then I emailed the BMJ the evidence.
Read 5 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

:(